// App-Quantinova.ai

609.0 : A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).

Researchers

Presenter

  • Anuradha Krishnamurthy

Principal Investigators

  • A. Dasari

  • Albert C. Lockhart

  • Mark N. Stein

  • Hanna Kelly Sanoff

  • James J. Lee

  • Aaron Richard Hansen

  • Tanios S. Bekaii-Saab

  • Usha Malhotra

  • Sarah Rippke

  • Sarah Lindsey Davis

  • Wells A. Messersmith

  • James C. Yao

  • Funda Meric-Bernstam

  • S. Gail Eckhardt

  • Christopher Hanyoung Lieu

Medical Centers

  • University of Colorado Cancer Center, Aurora, CO

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Washington University School of Medicine, St. Louis, MO

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Unv of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, NC

  • University of Pittsburgh, Pittsburgh, PA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Mayo Clinic Cancer Center, Phoenix, AZ

  • Roswell Park Cancer Institute, Buffalo, NY

  • University of Colorado Cancer Center, Aurora, CO

  • GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO

  • University of Colorado Hospital, Aurora, CO

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • cyclosporin A

  • cyclosporin

  • ARRY-142886

  • Oxaliplatin

  • selumetinib

  • Irinotecan

  • AZD-6244

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT02188264

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved